Droxidopa - Compound Summary (CID 3171) Also known as: |A,3-dihydroxytyrosine, ST50437521, 3,4-Dihydroxyphenylserine, threo-Dopaserine, L-Threodops Molecular Formula: C 9H 11NO 5 Molecular Weight: 213.18734 InChIKey: QXWYKJLNLSIPIN-UHFFFAOYSA-N A precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Administration of DL-threo-3,4-dihydroxyphenylserine has been claimed to result in an improvement in this phenomenon but controlled studies have failed to demonstrate improvement. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) From: MeSH |
| | |
Identification Related Records Pharmacology Biomedical Effects and Toxicity Literature Patents Biomolecular Interactions and Pathways Biological Test Results Classification Chemical and Physical Properties |